Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LY3884961

Other · developed by ELI LILLY &

Phase 1/2 Most advanced trial
LLY Developer

What is LY3884961?

LY3884961 is an agent administered as a single dose into the cisterna magna, studied in Parkinson disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Neurology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

Conditions studied

Parkinson Disease

More from ELI LILLY &

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind LY3884961

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.